Wall Street brokerages expect Omeros Co. (NASDAQ:OMER) to post ($0.72) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Omeros’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.70). Omeros posted earnings per share of ($0.07) in the same quarter last year, which would indicate a negative year-over-year growth rate of 928.6%. The company is scheduled to announce its next earnings results on Thursday, November 8th.
On average, analysts expect that Omeros will report full-year earnings of ($2.67) per share for the current financial year, with EPS estimates ranging from ($2.71) to ($2.62). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.13) per share, with EPS estimates ranging from ($2.04) to ($0.22). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Omeros.
Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.04). The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $1.84 million. The business’s quarterly revenue was down 90.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.33) earnings per share.
Several equities research analysts recently commented on the company. BidaskClub cut Omeros from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 6th. Zacks Investment Research raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 target price on shares of Omeros in a research report on Thursday, June 28th. ValuEngine raised Omeros from a “hold” rating to a “buy” rating in a research report on Friday, July 6th. Finally, Wedbush set a $20.00 target price on Omeros and gave the stock a “hold” rating in a research report on Friday, August 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $27.56.
Shares of NASDAQ OMER traded up $0.49 during trading hours on Monday, hitting $13.99. The stock had a trading volume of 607,922 shares, compared to its average volume of 1,037,468. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -17.71 and a beta of 3.49. Omeros has a 52 week low of $8.36 and a 52 week high of $27.00. The company has a debt-to-equity ratio of -2.31, a quick ratio of 3.94 and a current ratio of 3.95.
In other news, VP Marcia S. Kelbon sold 7,529 shares of the stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $25.75, for a total value of $193,871.75. Following the completion of the sale, the vice president now directly owns 227,645 shares of the company’s stock, valued at $5,861,858.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Marcia S. Kelbon sold 40,723 shares of the stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $21.56, for a total value of $877,987.88. Following the completion of the sale, the vice president now directly owns 219,645 shares of the company’s stock, valued at $4,735,546.20. The disclosure for this sale can be found here. 12.10% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Fox Run Management L.L.C. bought a new stake in shares of Omeros in the third quarter valued at approximately $424,000. Northern Trust Corp boosted its position in shares of Omeros by 2.1% in the second quarter. Northern Trust Corp now owns 615,377 shares of the biopharmaceutical company’s stock valued at $11,162,000 after acquiring an additional 12,827 shares during the period. Millennium Management LLC bought a new stake in shares of Omeros in the second quarter valued at approximately $8,513,000. Cubist Systematic Strategies LLC bought a new stake in shares of Omeros in the second quarter valued at approximately $274,000. Finally, BlueMountain Capital Management LLC bought a new stake in shares of Omeros in the second quarter valued at approximately $118,000. 48.11% of the stock is owned by institutional investors.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Article: Book Value Of Equity Per Share – BVPS Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.